Raptor Pharmaceutical Corp. (RPTP) Reaches New 52-Week High at $8.99
Raptor Pharmaceutical Corp. (NASDAQ:RPTP) shares hit a new 52-week high on Wednesday . The company traded as high as $8.99 and last traded at $8.99, with a volume of 2,368,290 shares changing hands. The stock had previously closed at $8.97.
A number of analysts have recently issued reports on RPTP shares. Cowen and Company downgraded shares of Raptor Pharmaceutical Corp. from an “outperform” rating to a “market perform” rating and set a $9.00 price objective on the stock. in a report on Friday, September 16th. Wedbush reiterated a “neutral” rating and issued a $4.00 price objective (down from $9.00) on shares of Raptor Pharmaceutical Corp. in a report on Monday, September 12th. FBR & Co reiterated a “hold” rating on shares of Raptor Pharmaceutical Corp. in a report on Thursday, September 8th. Citigroup Inc. downgraded shares of Raptor Pharmaceutical Corp. from a “buy” rating to a “neutral” rating and lifted their price objective for the company from $6.00 to $8.00 in a report on Monday, August 8th. Finally, Zacks Investment Research upgraded shares of Raptor Pharmaceutical Corp. from a “hold” rating to a “buy” rating and set a $7.50 price objective on the stock in a report on Thursday, August 11th. Six research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Raptor Pharmaceutical Corp. presently has a consensus rating of “Hold” and a consensus target price of $7.93.
The stock’s market cap is $766.90 million. The firm has a 50-day moving average price of $7.50 and a 200 day moving average price of $5.73.
Raptor Pharmaceutical Corp. (NASDAQ:RPTP) last posted its quarterly earnings results on Thursday, August 4th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.02. The firm had revenue of $32.05 million for the quarter, compared to analysts’ expectations of $28.52 million. Raptor Pharmaceutical Corp. had a negative return on equity of 66.67% and a negative net margin of 79.29%. The company’s revenue for the quarter was up 37.4% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.17) EPS. Analysts anticipate that Raptor Pharmaceutical Corp. will post ($0.90) EPS for the current year.
Several institutional investors have recently bought and sold shares of RPTP. Geode Capital Management LLC boosted its position in Raptor Pharmaceutical Corp. by 7.0% in the first quarter. Geode Capital Management LLC now owns 573,082 shares of the company’s stock worth $2,636,000 after buying an additional 37,740 shares during the last quarter. Renaissance Technologies LLC boosted its position in Raptor Pharmaceutical Corp. by 7.5% in the first quarter. Renaissance Technologies LLC now owns 572,946 shares of the company’s stock worth $2,636,000 after buying an additional 40,066 shares during the last quarter. Jacobs Levy Equity Management Inc. acquired a new position in Raptor Pharmaceutical Corp. during the first quarter worth about $771,000. Quantitative Systematic Strategies LLC acquired a new position in Raptor Pharmaceutical Corp. during the second quarter worth about $495,000. Finally, Bank of New York Mellon Corp boosted its position in Raptor Pharmaceutical Corp. by 2.7% in the second quarter. Bank of New York Mellon Corp now owns 455,391 shares of the company’s stock worth $2,446,000 after buying an additional 11,837 shares during the last quarter. Hedge funds and other institutional investors own 54.91% of the company’s stock.
About Raptor Pharmaceutical Corp.
Raptor Pharmaceutical Corp. (Raptor) is a biopharmaceutical company. The Company is focused on developing and commercializing transformative treatments for people affected by diseases. Its product, PROCYSBI (cysteamine bitartrate) is a delayed-release capsules for the management of nephropathic cystinosis in adults and children of over six years.
Receive News & Ratings for Raptor Pharmaceutical Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Raptor Pharmaceutical Corp. and related companies with MarketBeat.com's FREE daily email newsletter.